glp-1 drugs eli lilly Novo, weight-loss should be first option obesity treatments, European doctors say Eli Lilly Just Launched a

Novo Nordisk) 6.0mg/mL solution for injection in pre-filled pens

In addition, the drug combination also had no effect on the intestinal microbiome in elderly patients with T2DM, but there was an increase in the percentage of bacteria of the genus Alistipes

The Reasoning: After a thorough review, the agency found no clinical need for these drugs to be compounded when FDA-approved versions are available and not in shortage

they promote safe, effective, and sustainable weight loss

Novo is investing in expanding its production capacity and developing next-generation obesity treatments, such as an oral version of semaglutide, to maintain its competitive edge in the rapidly growing GLP-1 market

The clinical significance was highlighted by Lilly's leadership: "Obesity is a chronic, progressive disease, and sustaining weight loss remains a significant challenge for many," said Kenneth Custer , Ph.D., executive vice president and president, Lilly Cardiometabolic Health